Single User License
INR 101235
Site License
INR 202470
Corporate User License
INR 303705

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Seattle Genetics, Inc.-Product Pipeline Review-2015

Seattle Genetics, Inc.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Seattle Genetics, Inc.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Seattle Genetics, Inc.-Product Pipeline Review-2015', provides an overview of the Seattle Genetics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Seattle Genetics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Seattle Genetics, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Seattle Genetics, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Seattle Genetics, Inc.'s pipeline products

Reasons To Buy

Evaluate Seattle Genetics, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Seattle Genetics, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Seattle Genetics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Seattle Genetics, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Seattle Genetics, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Seattle Genetics, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Seattle Genetics, Inc. Snapshot 5

Seattle Genetics, Inc. Overview 5

Key Information 5

Key Facts 5

Seattle Genetics, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

Seattle Genetics, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Seattle Genetics, Inc.-Pipeline Products Glance 14

Seattle Genetics, Inc.-Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Seattle Genetics, Inc.-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Seattle Genetics, Inc.-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Seattle Genetics, Inc.-Drug Profiles 19

brentuximab vedotin 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

denintuzumab mafodotin 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

SEA-CD40 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

SGN-CD33A 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

SGN-CD70A 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

SGN-LIV1A 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

SGD-2083 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Seattle Genetics, Inc.-Pipeline Analysis 32

Seattle Genetics, Inc.-Pipeline Products by Target 32

Seattle Genetics, Inc.-Pipeline Products by Route of Administration 33

Seattle Genetics, Inc.-Pipeline Products by Molecule Type 34

Seattle Genetics, Inc.-Pipeline Products by Mechanism of Action 35

Seattle Genetics, Inc.-Recent Pipeline Updates 36

Seattle Genetics, Inc.-Dormant Projects 55

Seattle Genetics, Inc.-Discontinued Pipeline Products 56

Discontinued Pipeline Product Profiles 56

dacetuzumab 56

lintuzumab 56

SGN-15 56

vorsetuzumab 57

vorsetuzumab mafodotin 57

Seattle Genetics, Inc.-Company Statement 58

Seattle Genetics, Inc.-Locations And Subsidiaries 63

Head Office 63

Other Locations & Subsidiaries 63

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65

List of Tables

Seattle Genetics, Inc., Key Information 5

Seattle Genetics, Inc., Key Facts 5

Seattle Genetics, Inc.-Pipeline by Indication, 2015 7

Seattle Genetics, Inc.-Pipeline by Stage of Development, 2015 9

Seattle Genetics, Inc.-Monotherapy Products in Pipeline, 2015 10

Seattle Genetics, Inc.-Partnered Products in Pipeline, 2015 11

Seattle Genetics, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 12

Seattle Genetics, Inc.-Pre-Registration, 2015 14

Seattle Genetics, Inc.-Phase III, 2015 15

Seattle Genetics, Inc.-Phase II, 2015 16

Seattle Genetics, Inc.-Phase I, 2015 17

Seattle Genetics, Inc.-Preclinical, 2015 18

Seattle Genetics, Inc.-Pipeline by Target, 2015 32

Seattle Genetics, Inc.-Pipeline by Route of Administration, 2015 33

Seattle Genetics, Inc.-Pipeline by Molecule Type, 2015 34

Seattle Genetics, Inc.-Pipeline Products by Mechanism of Action, 2015 35

Seattle Genetics, Inc.-Recent Pipeline Updates, 2015 36

Seattle Genetics, Inc.-Dormant Developmental Projects,2015 55

Seattle Genetics, Inc.-Discontinued Pipeline Products, 2015 56

Seattle Genetics, Inc., Subsidiaries 63

List of Figures

Seattle Genetics, Inc.-Pipeline by Top 10 Indication, 2015 7

Seattle Genetics, Inc.-Pipeline by Stage of Development, 2015 9

Seattle Genetics, Inc.-Monotherapy Products in Pipeline, 2015 10

Seattle Genetics, Inc.-Partnered Products in Pipeline, 2015 11

Seattle Genetics, Inc.-Pipeline by Top 10 Target, 2015 32

Seattle Genetics, Inc.-Pipeline by Top 10 Route of Administration, 2015 33

Seattle Genetics, Inc.-Pipeline by Top 10 Molecule Type, 2015 34

Seattle Genetics, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Seattle Genetics, Inc.; Seattle Genetics, Inc. - Key Therapeutics; Seattle Genetics, Inc. - Pipeline Overview and Promising Molecules; Seattle Genetics, Inc. - News; Seattle Genetics, Inc. - Latest Updates; Seattle Genetics, Inc. - Pipeline; Seattle Genetics, Inc. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com